Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 228
Filter
4.
Clin Exp Dermatol ; 46(5): 896-900, 2021 Jul.
Article in English | MEDLINE | ID: mdl-33638914

ABSTRACT

Chloracne, also known as metabolizing acquired dioxin-induced skin hamartomas (MADISH), is a rare disfiguring disease related to dioxin exposure. There is a paucity of literature on the clinical manifestations and pathogenesis of chloracne/MADISH. The aim of this study was to assess the clinical features of this very unusual acneiform eruption and to explore the pathogenesis of the disease. This was a retrospective, observational report study was conducted on five patients belonging to the same nuclear family (father, mother and three children) and a relative (father's brother) living in the same house. Histopathological, immunohistochemical, laboratory and toxicological analyses were performed for all patients. The results suggest that CYP1A1 in human skin is a diagnostic biomarker in chloracne, and was positive for all the patients in our sample. Tetrachlorodibenzo-p-dioxin is the most investigated dioxin responsible for chloracne; however, several other agonists, whether dioxin-like or not, can activate the aryl hydrocarbon receptor. To our knowledge, this Italian case series is the first study to suggest polychlorinated biphenyls as a possible cause of an overstimulation of aryl hydrocarbons causing the consequent acneiform eruption.


Subject(s)
Acneiform Eruptions/pathology , Chloracne/metabolism , Cytochrome P-450 CYP1A1/metabolism , Dioxins/toxicity , Polychlorinated Dibenzodioxins/toxicity , Acneiform Eruptions/etiology , Acneiform Eruptions/metabolism , Adult , Biomarkers/metabolism , Child , Chloracne/diagnosis , Chloracne/etiology , Environmental Exposure/adverse effects , Female , Humans , Immunohistochemistry/methods , Italy/epidemiology , Male , Pakistan/ethnology , Polychlorinated Biphenyls/adverse effects , Polychlorinated Biphenyls/chemistry , Receptors, Aryl Hydrocarbon/chemistry , Receptors, Aryl Hydrocarbon/metabolism , Retrospective Studies
8.
J Eur Acad Dermatol Venereol ; 33(4): 742-752, 2019 Apr.
Article in English | MEDLINE | ID: mdl-29924416

ABSTRACT

BACKGROUND: Anti-nuclear antibodies (ANA), anti-extractable nuclear antigens (ENA) and anti-dsDNA antibodies are often associated with cutaneous lupus erythematosus (CLE), with variable frequency depending on skin subtype. However, specific data based on large case-series on the pathogenetic, diagnostic and prognostic meaning of such autoantibodies are still lacking. OBJECTIVE: To characterize the correlations between CLE subtypes as well as LE-non-specific skin lesions and their autoantibody pattern. METHODS: Epidemiological, clinical and immunopathological data of 619 Italian patients with CLE and LE-non-specific skin lesions were analysed. Differences in age, sex, clinical features and autoantibody profile were evaluated in each LE subgroup. RESULTS: Anti-nuclear antibodies (P < 0.0001), anti-dsDNA (P < 0.0001), ENA (P = 0.001), anti-Sm (P = 0.001), anti-RNP (P = 0.004) and anti-histone (P = 0.005) antibodies were associated with SLE. A strong association between ANA (P < 0.0001) and anti-dsDNA (P < 0.0001) and female gender was also found: positive ANA and positive anti-dsDNA had a higher prevalence among females. Chronic CLE resulted to be negatively associated with ENA (OR = 0.51, P < 0.0001), anti-Ro/SSA (OR = 0.49, P < 0.0001) and anti-dsDNA (OR = 0.37, P < 0.0001). Intermittent CLE resulted to be negatively associated with ENA (OR = 0.50, P = 0.007) and ANA (OR = 0.61, P = 0.025). Subacute CLE resulted to be associated with ENA (OR = 5.19, P < 0.0001), anti-Ro/SSA (OR = 3.83, P < 0.0001), anti-Smith (OR = 2.95, P = 0.004) and anti-RNP (OR = 3.18, P = 0.007). Acute CLE resulted to be strongly associated with anti-dsDNA (OR = 6.0, P < 0.0001) and ANA (OR = 18.1, P < 0.0001). LE-non-specific skin lesions resulted to be significantly associated with systemic involvement. Livedo reticularis was significantly associated with ENA (P = 0.007) and anti-Ro/SSA (P = 0.036). Palpable purpura and periungual telangiectasia were significantly associated with ANA. CONCLUSION: According to our findings, some well-known associations between CLE subtypes and autoantibody profile were confirmed; moreover, specific association between autoantibodies and LE-non-specific skin lesions was highlighted. A strict association between anti-ENA and anti-Ro/SSA antibodies and livedo reticularis, ANA and palpable purpura, and ANA and periungual telangiectasia was evidenced.


Subject(s)
Antibodies, Antinuclear/blood , Lupus Erythematosus, Cutaneous/blood , Lupus Erythematosus, Cutaneous/epidemiology , Acute Disease , Adult , Antigens, Nuclear/immunology , Autoantigens/immunology , Chronic Disease , Cross-Sectional Studies , DNA/immunology , Female , Histones/immunology , Humans , Italy/epidemiology , Livedo Reticularis/blood , Livedo Reticularis/epidemiology , Male , Middle Aged , Purpura/blood , Purpura/epidemiology , RNA, Small Cytoplasmic/immunology , Ribonucleoproteins/immunology , Sex Factors , Telangiectasis/blood , Telangiectasis/epidemiology
9.
Nutr Metab Cardiovasc Dis ; 27(12): 1098-1107, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29174026

ABSTRACT

BACKGROUND AND AIMS: We assessed post-marketing safety of sodium-glucose co-transporter-2 inhibitors (SGLT2-Is) by analyzing adverse events (AEs) reported in international pharmacovigilance databases. METHODS AND RESULTS: Eudravigilance, WHO-Vigibase (as of Feb 25, 2017) and the FDA Adverse Event Reporting System (FAERS, from 2004 to 2016 second quarter) were queried to extract AEs recording SGLT2-Is as suspect. Disproportionality analyses (case/non-case method) were performed in FAERS by calculating the reporting odds ratios (RORs) from System Organ Classes (SOCs) to Preferred Terms (PTs) (precise clinical entities). Potential signals were defined by statistically-significant ROR (lower limit of the 95% confidence interval - LL95%CI - >1) undetected by literature analysis (as of December 2016). SGLT2-Is were recorded in 7972, 19,775, 11,137 reports (Eudravigilance, WHO-Vigibase and FAERS, respectively); in FAERS, statistically significant ROR emerged for the following SOCs: "infections and infestations" (N = 2162; LL95%CI = 3.25), "metabolism and nutrition disorders" (2278; 1.36), "renal and urinary disorders" (1665; 2.31), "reproductive system and breast disorders" (471; 4.85), "skin and subcutaneous tissue disorders" (1136; 1.52). Skin toxicity emerged as potential signal (e.g., rash, photosensitivity, urticaria as PTs), both for SGLT2-Is as a class and as individual drugs. Severe adverse skin events (81 reports, 7% of the skin cases) mainly occurred in females aged 18-65 using SGLT2-Is as single antidiabetic regimen. CONCLUSION: Among antidiabetics, SGLT2-Is are associated with higher reporting of infections, metabolism, renal and reproductive AEs, corroborating clinical trial evidence. Their large reporting patterns and the unexpected signal of skin toxicity justify active vigilance by clinicians and "real-time" monitoring by pharmacovigilance experts.


Subject(s)
Adverse Drug Reaction Reporting Systems , Diabetes Mellitus, Type 2/drug therapy , Drug-Related Side Effects and Adverse Reactions/epidemiology , Hypoglycemic Agents/adverse effects , Pharmacovigilance , Sodium-Glucose Transporter 2 Inhibitors , Adolescent , Adult , Aged , Child , Child, Preschool , Databases, Factual , Diabetes Mellitus, Type 2/metabolism , Drug-Related Side Effects and Adverse Reactions/diagnosis , Female , Humans , Infant , Infant, Newborn , Male , Middle Aged , Patient Safety , Risk Assessment , Risk Factors , Sodium-Glucose Transporter 2/metabolism , Time Factors , Young Adult
11.
G Ital Dermatol Venereol ; 150(2): 165-7, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25876144

ABSTRACT

Vasculitides are a challenge to the clinician, in terms of both diagnosis and therapy. Multiple classification systems have been implemented and the numerous classification schemes reflect the complexity of establishing a simple classification that could be functional for daily care. Although vasculitis classification has become increasingly elaborated, some areas remain ill defined. Some forms of vasculitis are still difficult to assign to a specific disease entity. Generally accepted operational criteria are available for many vasculitides, but for some entities there are no effective criteria. Moreover, diagnostic criteria for vasculitis with sufficient strength and/or confidence that can be universally accepted are not yet available. The need for diagnostic criteria validated and agreed upon is particularly relevant in the context of cutaneous vasculitis. The project of the SIDeMaST Italian Group of Immunopathology on cutaneous vasculitis is a national prospective observational study designed to develop and validate diagnostic criteria and to improve and validate classification criteria for cutaneous small vessel vasculitis also known as leukocytoclastic vasculitis (CLV). Primary objective of the study will also be that of developing the CUtaneous VAsculitis Severity Index (CUVASI). Secondary objectives of the project will be: 1) definition of the etiological agents that are most frequently associated with CLV; 2) search for possible correlations between causative agent and peculiar clinical and/or histopathological aspects; 3) evaluation of immunofluorescence pattern observed in this specific group of primitive cutaneous vasculitis in order to characterize the diagnostic sensitivity and specificity of this technique; 4) identification of a set of clinical investigations and laboratory tests to be performed for a correct CLV assessment. Actually 15 Italian dermatological clinics are contributing to the project and anticipated recruiting >100 patients with CLV. A pilot retrospective study to assess the feasibility of the project is going to be launched and if its results are positive then the prospective study will be started and it promises to be a unique opportunity to evaluate a large database on CLV in Italian population.


Subject(s)
Skin Diseases, Vascular/diagnosis , Vasculitis/diagnosis , Humans , Italy , Pilot Projects , Research Design , Sensitivity and Specificity , Severity of Illness Index , Skin Diseases, Vascular/classification , Skin Diseases, Vascular/pathology , Validation Studies as Topic , Vasculitis/classification , Vasculitis/pathology
15.
Dermatology ; 220(2): 138-42, 2010.
Article in English | MEDLINE | ID: mdl-20110633

ABSTRACT

BACKGROUND: Parvovirus B19 is the aetiological agent of erythema infectiosum. The presence of B19 DNA in lesional skin of other cutaneous manifestations has frequently been reported although there is disagreement on the role of the B19 virus in tissues. OBJECTIVES: To investigate the presence of B19 DNA (1) in skin lesions of patients with a described B19-related disease, (2) in skin lesions of B19-unrelated diseases and (3) in healthy skin. METHODS: A total of 121 skin samples were examined for the presence of B19 DNA by PCR assays and peptide-nucleic-acid-based in situ hybridisation techniques. RESULTS: B19 DNA was detected in 11/38 (28.9%) pityriasis lichenoides, 8/30 (26.7%) melanocytic naevi, 5/29 (17.2%) primary melanomas and 6/24 (25.0%) healthy skin biopsies. A difference in B19 DNA prevalence was observed in specimens grouped according to age, irrespective of pathologies. CONCLUSIONS: B19 DNA can be found in skin tissues of patients with pityriasis lichenoides as well as in lesions not related to B19 infection and in healthy controls. B19 DNA can be detected in skin of young subjects in a significantly high rate compared to adults, suggesting that viral persistence may be the usual outcome after primary infection.


Subject(s)
Erythema Infectiosum/virology , Parvovirus B19, Human/isolation & purification , Skin/virology , Adult , Aged , Aged, 80 and over , DNA, Viral/analysis , Female , Humans , Male , Melanoma/virology , Middle Aged , Nevus/virology , Pityriasis Lichenoides/virology , Skin Neoplasms/virology
20.
Int J Immunopathol Pharmacol ; 20(3): 557-66, 2007.
Article in English | MEDLINE | ID: mdl-17880768

ABSTRACT

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are considered to be severity variants of the same disease, which is almost always associated with drug intake. In contrast, erythema multiforme (EM) is a disorder regarded as only rarely caused by drugs. Keratinocyte apoptosis has been shown to play an important part in the pathogenesis of SJS and TEN, whilst its role in EM remains controversial. To determine the expression of apoptosis-associated molecules Fas, Fas ligand (FasL), Bcl-2 and Bax in the above disorders, an immunohistochemical analysis was performed. We studied both lesional skin from thirty patients having drug-induced EM and 5 cases classified within the SJS/TEN spec nottrum and normal skin samples. We found a keratinocyte overexpression of Fas antigen, an important molecule mediating apoptosis, not only in SJS and TEN but also in EM. Another noteworthy finding was the strong expression of Bcl-2, a protein known as blocking apoptosis, along the basal layer and in the dermal infiltrate both in SJS/TEN and in EM. Taken together, these findings suggest that Fas-dependent keratinocyte apoptosis may play a part in the pathogenesis of both SJS/TEN and EM. Fas-mediated cell death may be partially suppressed by the Bcl-2 protein.


Subject(s)
Antigens/biosynthesis , Apoptosis/drug effects , Erythema Multiforme , Skin/drug effects , Stevens-Johnson Syndrome , Antigens/immunology , Apoptosis/immunology , Biomarkers/analysis , CD8-Positive T-Lymphocytes/immunology , Erythema Multiforme/chemically induced , Erythema Multiforme/immunology , Erythema Multiforme/pathology , Fas Ligand Protein/biosynthesis , Fas Ligand Protein/immunology , Humans , Immunohistochemistry , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Proto-Oncogene Proteins c-bcl-2/immunology , Skin/immunology , Skin/metabolism , Skin/pathology , Stevens-Johnson Syndrome/chemically induced , Stevens-Johnson Syndrome/etiology , Stevens-Johnson Syndrome/immunology , Stevens-Johnson Syndrome/pathology , bcl-2-Associated X Protein/biosynthesis , bcl-2-Associated X Protein/immunology , fas Receptor/biosynthesis , fas Receptor/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...